Tianjin Lisheng Pharmaceutical Co Ltd (002393) — Cash Flow-to-Debt Ratio
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has a Cash Flow-to-Debt Ratio of 0.32x as of December 2025, meaning its operating cash flow of CN¥287.81 Million could theoretically repay 0% of its total liabilities (CN¥890.89 Million) in one year. See 002393 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tianjin Lisheng Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio (2007–2025)
Historical debt coverage capacity for Tianjin Lisheng Pharmaceutical Co Ltd across 19 annual periods. For the full cash flow conversion analysis, see Tianjin Lisheng Pharmaceutical Co Ltd cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Tianjin Lisheng Pharmaceutical Co Ltd (2007–2025)
Year-by-year debt coverage analysis for Tianjin Lisheng Pharmaceutical Co Ltd. Check 002393 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.51x | CN¥451.85 Million | CN¥890.89 Million | ▲ +466.3% |
| 2024 | 0.09x | CN¥88.26 Million | CN¥985.54 Million | ▼ -62.5% |
| 2023 | 0.24x | CN¥209.51 Million | CN¥877.17 Million | ▼ -32.1% |
| 2022 | 0.35x | CN¥331.38 Million | CN¥941.66 Million | ▲ +39.9% |
| 2021 | 0.25x | CN¥196.34 Million | CN¥780.42 Million | ▲ +137.2% |
| 2020 | 0.11x | CN¥76.37 Million | CN¥720.09 Million | ▼ -66.2% |
| 2019 | 0.31x | CN¥268.33 Million | CN¥855.85 Million | ▲ +35.8% |
| 2018 | 0.23x | CN¥162.69 Million | CN¥704.85 Million | ▼ -22.4% |
| 2017 | 0.30x | CN¥179.25 Million | CN¥602.32 Million | ▼ -19.3% |
| 2016 | 0.37x | CN¥173.60 Million | CN¥470.60 Million | ▼ -18.2% |
| 2015 | 0.45x | CN¥198.13 Million | CN¥439.50 Million | ▲ +110.9% |
| 2014 | 0.21x | CN¥72.24 Million | CN¥337.89 Million | ▼ -78.0% |
| 2013 | 0.97x | CN¥289.62 Million | CN¥298.20 Million | ▼ -42.6% |
| 2012 | 1.69x | CN¥250.72 Million | CN¥148.13 Million | ▼ -19.4% |
| 2011 | 2.10x | CN¥134.58 Million | CN¥64.07 Million | ▼ -13.2% |
| 2010 | 2.42x | CN¥186.55 Million | CN¥77.12 Million | ▲ +407.2% |
| 2009 | 0.48x | CN¥196.14 Million | CN¥411.26 Million | ▲ +1.9% |
| 2008 | 0.47x | CN¥126.59 Million | CN¥270.58 Million | ▲ +18.2% |
| 2007 | 0.40x | CN¥174.94 Million | CN¥441.87 Million | — |